GPCR · Structure Therapeutics Inc.
$21.10
-0.42% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
<$1M
Trailing P/E
—
Forward P/E
-10.0
Dividend yield
0.0%
Beta
-1.37
Avg volume
1M
Employees
0K
Daily Change %
-0.42%
5 Days Change
-3.78%
10 Days Change
0.09%
30 Days Change
-41.27%
60 Days Change
-55.46%
Month to Day Change
-27.19%
Year to Day Change
-69.66%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GPCR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Citigroup
Buy$97.00
+359.7% vs priceJP Morgan
Overweight$105
+397.6% vs priceMorgan Stanley
Overweight$125
+492.4% vs priceJefferies
Buy$125
+492.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Citizens | Reiterates | Market Outperform | $110 |
| 2026-08-07 | Citigroup | Maintains | Buy | $100 → $97.00 |
| 2026-08-07 | Citizens | Maintains | Market Outperform | $113 → $110 |
| 2026-06-11 | HC Wainwright & Co. | Maintains | Buy | $100 → $70.00 |
| 2026-04-27 | Canaccord Genuity | Initiates | Buy | $0.00 → $101 |
| 2026-03-16 | HC Wainwright & Co. | Maintains | Buy | $114 → $100 |
| 2026-03-02 | HC Wainwright & Co. | Maintains | Buy | $90.00 → $114 |
| 2026-02-27 | Citizens | Maintains | Market Outperform | $120 → $113 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- bullish: RSI (14): RSI is 20 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 41.3% below the 50-day MA ($35.94).
- bearish: Price vs 200-day MA: Trading 57.9% below the 200-day MA ($50.13).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.36) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($21.08).
GPCR Price Chart
Loading chart for GPCR…
Fundamentals
About Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.